DOLENIO Film-coated tablets (2018)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Dolenio 500 mg film-coated tablets.
Qualitative and quantitative composition
One film-coated tablet contains 628.2 mg of Glucosamine sulphate sodium chloride equivalent to 500 mg Glucosamine sulphate or 393 mg glucosamine. Excipient with known effect: One tablet contains Sodium ...
Pharmaceutical form
Film-coated tablet. White to off white, oval shaped, bi-convex film-coated tablets.
Therapeutic indications
Relief of symptoms in mild to moderate osteoarthritis of the knee.
Posology and method of administration
Adults The recommended dose is 1178 mg of Glucosamine (1500 mg Glucosamine sulphate) to be taken once daily with a glass of water. This quantity corresponds to: 3 tablets of Dolenio 500 mg to be taken ...
Contraindications
Hypersensitivity to shellfish as the active ingredient is obtained from shellfish. Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Children under 2 years of ...
Special warnings and precautions for use
A doctor should be consulted to rule out the presence of joint disease for which other treatment should be considered. In patients with impaired glucose tolerance, monitoring of the blood glucose levels ...
Interaction with other medicinal products and other forms of interaction
Increased effect of coumarin anticoagulants (e.g. warfarin) during concomitant treatment with glucosamine has been reported. Patients treated with coumarin anticoagulants should therefore be monitored ...
Pregnancy and lactation
Pregnancy There are inadequate data concerning the use of glucosamine in pregnant women. From animal studies only insufficient data are available. Glucosamine should not be used during pregnancy. Breast ...
Effects on ability to drive and use machines
No studies on the effects on the ability to drive or use machines have been performed. If dizziness or drowsiness is experienced, car driving and the operating of machinery are not recommended.
Undesirable effects
The most common adverse reactions associated with treatment with glucosamine are nausea, abdominal pain, indigestion, constipation, and diarrhoea. In addition, headache, tiredness, rash, itching, and flushing ...
Overdose
Signs and symptoms of accidental or intentional overdose with glucosamine might include headache, dizziness, disorientation, arthralgia, nausea, vomiting, diarrhoea or constipation. In case of overdose, ...
Pharmacodynamic properties
Pharmacotherapeutic group: Other anti-inflammatory and antirheumatic agents, non-steroids ATC code: M01AX05 Glucosamine is an endogenous substance, a normal constituent of the polysaccharide chains of ...
Pharmacokinetic properties
Glucosamine is a relatively small molecule (molecular mass 179), which is easily dissolved in water and soluble in hydrophilic organic solvents. The available information on the pharmacokinetics of glucosamine ...
Preclinical safety data
D-glucosamine has low acute toxicity. Animal experimental data relating to toxicity during repeated administration, reproduction toxicity or carcinogenicity is lacking for glucosamine. Glucosamine is not ...
List of excipients
Core tablet: Povidone K30 Macrogol 4000 Magnesium Stearate Film-Coating: Hypromellose Titanium Dioxide (E171) Talc Propylene glycol Polysorbate 80
Incompatibilities
Not applicable.
Shelf life
Shelf life: 3 years.
Special precautions for storage
This medicinal product does not require any special storage conditions.
Nature and contents of container
Alu/PVC/PVDC Blister packs. Pack-sizes: 90, 180, 270 film-coated tablets. Not all pack sizes may be marketed.
Special precautions for disposal and other handling
No special requirements.
Marketing authorization holder
Blue Bio Pharmaceuticals Ltd., 5<sup>th</sup> Floor, Beaux Lane House, Mercer Street Lower, Dublin 2, Ireland
Marketing authorization number(s)
PL 33831/0002
Date of first authorization / renewal of the authorization
01/03/2012
Date of revision of the text
04/05/2018
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
